Unique ID issued by UMIN | UMIN000010323 |
---|---|
Receipt number | R000001616 |
Scientific Title | A study to evaluate the effect of ezetimibe and rosuvastatin on intravascular ultrasound-derived coronary atheroma and lipid lowering effect. |
Date of disclosure of the study information | 2013/03/27 |
Last modified on | 2017/07/25 13:25:11 |
A study to evaluate the effect of ezetimibe and rosuvastatin on intravascular ultrasound-derived coronary atheroma and lipid lowering effect.
Mie study of Ezetimibe and Rosvastatin for attenuation of coronary artery atherosclerosis by using Intravascular ultrasound (MERIT study)
A study to evaluate the effect of ezetimibe and rosuvastatin on intravascular ultrasound-derived coronary atheroma and lipid lowering effect.
Mie study of Ezetimibe and Rosvastatin for attenuation of coronary artery atherosclerosis by using Intravascular ultrasound (MERIT study)
Japan |
dyslipidemia
Cardiology |
Others
NO
Compare of the coronary artery plaque volume between statin only and statin eith ezetimibe by intravascular-ultrasound.
Safety,Efficacy
The change in coronary atheroma by serial volumetoric intravascular-ultrasound analysis
body mass index, serum LDL-C, HDL-C, TG, non-HDL, small dense LDL, hs-CRP, HOMA-IR, oxidized LDL and hs-CRP
Interventional
Parallel
Randomized
Open -no one is blinded
Active
2
Treatment
Medicine |
statin only arm
statin with ezetimibe arm
20 | years-old | <= |
Not applicable |
Male and Female
men and women abobe 20 years of age and LDL-chol moreover 100mg/dl with a clinical indication for coronary catheterization therapy and provided written informed consent
1, privious allergy for ezetimibe or any of statins
2, contraindication for rosuvastatin and already recieved rosuvastatin
3, secondary dyslipidemia
4, history of acute coronary syndrome within 3months before study entry
5, congestive heart failure (NYHA 3 or 4)
6, low left ventricular contractility
7, inducation for coronary artery bypass graft
8, poor control HTN patient (systolic BP over 220mmHg, diastolic BP over 110mmHg)
9, poor control diabetic patient (HbA1c over 9.5%)
10, hemodialysis patient
11, severe renal dysfunction (30 over CCr or serum Cre over 2.0)
12, serum CK over 300
13, severe liver dysfunction
50
1st name | |
Middle name | |
Last name | Mashio Nakamura |
Mie University Graduate School of Medicine
Department of Cardiovascular Research
2-174 Edibashi, Tsu, Mie
059-231-5015
mashio@clin.medic.mie-u.ac.jp
1st name | |
Middle name | |
Last name | Jun Masuda |
Mie University Graduate School of Medicine
Department of Cardiology and Nephrology
2-174 Edibashi, Tsu, Mie
059-231-5015
jun-m@clin.medic.mie-u.ac.jp
Department of Cardiology and Nephrology, Mie University Graduate School of Medicine
Department of Cardiology and Nephrology, Mie University Graduate School of Medicine
Japan
Clinical Research Support Center, Mie University Hospital
NO
三重大学医学部附属病院(三重県)
Mie University Hospital (Mie)
2013 | Year | 03 | Month | 27 | Day |
Published
https://www.jstage.jst.go.jp/article/ihj/56/3/56_14-311/_pdf
Intensive lipid-lowering therapy with ezetimibe provide greater reduction in the percent change in plaque volume (PV), the primary endpoint, than the statin monotherapy group (-13.2% versus -3.1%, respectively, P = 0.050).Moreover, percent change in PV showed positive correlations with percent change of LDL-C (r = 0.384, P = 0.015). Intensive lipid-lowering therapy with ezetimibe added to usual-dose statin may provide significant incremental reduction in coronary plaques compared with usual-dose statin monotherapy.
Main results already published
2008 | Year | 08 | Month | 01 | Day |
2008 | Year | 10 | Month | 01 | Day |
2013 | Year | 04 | Month | 05 | Day |
2013 | Year | 04 | Month | 11 | Day |
2013 | Year | 05 | Month | 27 | Day |
2013 | Year | 11 | Month | 06 | Day |
2013 | Year | 03 | Month | 27 | Day |
2017 | Year | 07 | Month | 25 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001616